These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 26589238)

  • 81. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
    Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
    Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
    Kim SC; Schneeweiss S; Glynn RJ; Doherty M; Goldfine AB; Solomon DH
    Ann Rheum Dis; 2015 Nov; 74(11):1968-75. PubMed ID: 24919467
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Contrasting effects on the risk of macrovascular and microvascular events of antihyperglycemic drugs that enhance sodium excretion and lower blood pressure.
    Packer M
    Diabet Med; 2018 Jun; 35(6):707-713. PubMed ID: 29532519
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Switching to Versus Addition of Incretin-Based Drugs Among Patients With Type 2 Diabetes Taking Sodium-Glucose Cotransporter-2 Inhibitors.
    Lau KTK; Wong CKH; Au ICH; Lau WCY; Man KKC; Chui CSL; Wong ICK
    J Am Heart Assoc; 2022 Apr; 11(7):e023489. PubMed ID: 35322676
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A nationwide propensity-score matched cohort study.
    Kim J; Han K; Kim B; Baek KH; Song KH; Kim MK; Kwon HS
    Diabetes Res Clin Pract; 2022 Dec; 194():110187. PubMed ID: 36442545
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Trends in Prescribing Preferences for Antidiabetic Medications Among Patients With Type 2 Diabetes in the U.K. With and Without Chronic Kidney Disease, 2006-2020.
    Liaw J; Harhay M; Setoguchi S; Gerhard T; Dave CV
    Diabetes Care; 2022 Oct; 45(10):2316-2325. PubMed ID: 35984049
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes.
    Chi C; Snaith J; Gunton JE
    Heart Lung Circ; 2017 Nov; 26(11):1133-1141. PubMed ID: 28473214
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The Association of Joint Pain and Dipeptidyl Peptidase-4 Inhibitor Use Among U.S. Adults With Type-2 Diabetes Mellitus.
    Rai P; Zhao X; Sambamoorthi U
    J Pain Palliat Care Pharmacother; 2018; 32(2-3):90-97. PubMed ID: 30676844
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Newer anti - diabetic therapies and chronic kidney disease].
    Di Lullo L; Ronco C; Barbera V; Cozzolino M; Santoboni F; Villani A; De Pascalis A; Bellasi A
    G Ital Nefrol; 2017; 34(1):. PubMed ID: 28177092
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Not Available].
    Toft E; Rydén M
    Lakartidningen; 2018 Feb; 115():. PubMed ID: 29461566
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors.
    Del Prato S; Chilton R
    Diabetes Obes Metab; 2018 Apr; 20(4):786-799. PubMed ID: 29171700
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Beneficial effects of combination therapy of canagliflozin and teneligliptin on diabetic polyneuropathy and β-cell volume density in spontaneously type 2 diabetic Goto-Kakizaki rats.
    Guo D; Mizukami H; Osonoi S; Takahashi K; Ogasawara S; Kudo K; Sasaki T; Yagihashi S
    Metabolism; 2020 Jun; 107():154232. PubMed ID: 32302619
    [TBL] [Abstract][Full Text] [Related]  

  • 93. New Agents for the Treatment of Type 2 Diabetes.
    Libianto R; Ekinci EI
    Crit Care Clin; 2019 Apr; 35(2):315-328. PubMed ID: 30784612
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Targeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy.
    Iacobellis G; Basilico S; Malavazos AE
    Handb Exp Pharmacol; 2022; 274():93-108. PubMed ID: 35156138
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Glucose lowering and the kidney: are all drug classes equal?
    Wong MG; Jardine M; Perkovic V
    Lancet Diabetes Endocrinol; 2018 Nov; 6(11):835-837. PubMed ID: 30292590
    [No Abstract]   [Full Text] [Related]  

  • 96. Dipeptidyl peptidase-4 inhibitor use is not associated with elevated risk of severe joint pain in patients with type 2 diabetes: a population-based cohort study.
    Hou WH; Chang KC; Li CY; Ou HT
    Pain; 2016 Sep; 157(9):1954-1959. PubMed ID: 27127847
    [TBL] [Abstract][Full Text] [Related]  

  • 97. How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?
    Sukkar L; Young T; Jardine MJ
    Kidney Blood Press Res; 2020; 45(6):823-836. PubMed ID: 33271545
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors.
    Fadini GP; Bonora BM; Mayur S; Rigato M; Avogaro A
    Diabetes Obes Metab; 2018 Mar; 20(3):740-744. PubMed ID: 29053207
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study.
    Jermendy G; Kiss Z; Rokszin G; Abonyi-Tóth Z; Wittmann I; Kempler P
    Diabetes Ther; 2018 Oct; 9(5):2133-2141. PubMed ID: 30120754
    [TBL] [Abstract][Full Text] [Related]  

  • 100. [Use of dipeptidyl peptidase-4 inhibitors in diabetic patients in special situations].
    Seguí Díaz M
    Semergen; 2018 Jun; 44 Suppl 1():18-25. PubMed ID: 30322469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.